MD20170025A2 - Tratamente terapeutice pe bază de anamorelin - Google Patents

Tratamente terapeutice pe bază de anamorelin Download PDF

Info

Publication number
MD20170025A2
MD20170025A2 MDA20170025A MD20170025A MD20170025A2 MD 20170025 A2 MD20170025 A2 MD 20170025A2 MD A20170025 A MDA20170025 A MD A20170025A MD 20170025 A MD20170025 A MD 20170025A MD 20170025 A2 MD20170025 A2 MD 20170025A2
Authority
MD
Moldova
Prior art keywords
anamorelin
therapeutically effective
therapeutic treatments
treatments based
condition
Prior art date
Application number
MDA20170025A
Other languages
English (en)
Russian (ru)
Other versions
MD4710C1 (ro
MD4710B1 (ro
Inventor
Уильям МЭНН
Джон ФРЕНД
Уильям ПОЛВИНО
Сьюзен АЛЛЕН
М Лу
Элизабет ДУУС
Энрико БАРОНИ
Рубен ДЖИОРДЖИНО
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20170025(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MD20170025A2 publication Critical patent/MD20170025A2/ro
Publication of MD4710B1 publication Critical patent/MD4710B1/ro
Publication of MD4710C1 publication Critical patent/MD4710C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Invenţia se referă la metode de tratament al stărilor legate de afecţiuni canceromatoase cu utilizarea anamorelinului. Exemplul de realizare principal se referă la starea deosebită a pacienţilor ce defineşte starea dată prin tratamentul caşexiei la un pacient uman cu cancer, care cuprinde administrarea pacientului respectiv a unei cantităţi eficiente terapeutic de anamorelin pe parcursul unei perioade de timp eficiente terapeutic şi la capacitatea surprinzătoare a anamorelinului de a spori masa non-lipidică a corpului în populaţia dată.
MDA20170025A 2014-09-04 2015-08-28 Tratamente terapeutice pe bază de anamorelin MD4710C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (3)

Publication Number Publication Date
MD20170025A2 true MD20170025A2 (ro) 2017-07-31
MD4710B1 MD4710B1 (ro) 2020-09-30
MD4710C1 MD4710C1 (ro) 2021-04-30

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20170025A MD4710C1 (ro) 2014-09-04 2015-08-28 Tratamente terapeutice pe bază de anamorelin

Country Status (44)

Country Link
US (5) US9675600B2 (ro)
EP (2) EP3590338A3 (ro)
JP (3) JP6356907B2 (ro)
KR (3) KR101881264B1 (ro)
CN (5) CN113577073A (ro)
AP (1) AP2017009772A0 (ro)
AR (1) AR103118A1 (ro)
AU (1) AU2015312231B2 (ro)
BR (1) BR112017003552A2 (ro)
CA (1) CA2959158A1 (ro)
CL (1) CL2017000494A1 (ro)
CO (1) CO2017003263A2 (ro)
CR (1) CR20170121A (ro)
CY (1) CY1122746T1 (ro)
DK (1) DK3188599T3 (ro)
DO (1) DOP2017000055A (ro)
EA (1) EA035578B1 (ro)
EC (1) ECSP17019893A (ro)
ES (1) ES2761777T3 (ro)
GE (2) GEAP201814459A (ro)
HR (1) HRP20192345T1 (ro)
HU (1) HUE046894T2 (ro)
IL (1) IL250692B (ro)
JO (1) JO3541B1 (ro)
LT (1) LT3188599T (ro)
MA (1) MA40607B1 (ro)
MD (1) MD4710C1 (ro)
ME (1) ME03597B (ro)
MX (1) MX361741B (ro)
MY (1) MY187167A (ro)
NI (1) NI201700024A (ro)
PE (1) PE20171109A1 (ro)
PH (1) PH12017500392B1 (ro)
PL (1) PL3188599T3 (ro)
PT (1) PT3188599T (ro)
RS (1) RS59751B1 (ro)
SG (1) SG11201701567UA (ro)
SI (1) SI3188599T1 (ro)
SV (1) SV2017005400A (ro)
TN (1) TN2017000040A1 (ro)
TW (1) TWI639429B (ro)
UA (1) UA120765C2 (ro)
UY (1) UY36286A (ro)
WO (1) WO2016036598A1 (ro)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
MY187167A (en) 2014-09-04 2021-09-07 Helsinn Healthcare Sa Medical treatments based on anamorelin
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. MAINTENANCE DOSE ORAL PEANUT IMMUNOTHERAPY
EP3897681A4 (en) 2018-12-20 2022-10-26 Société des Produits Nestlé S.A. DOSING SCHEDULE APPLICABLE FOR ORAL IMMUNOTHERAPY AGAINST PEANUT FOR MISSED DOSES
JP7574222B2 (ja) 2019-05-10 2024-10-28 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ピーナツアレルギー患者の生活の質を改善するための方法
CN115569119A (zh) 2019-08-30 2023-01-06 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
US20240139176A1 (en) 2019-10-24 2024-05-02 Toray Industries, Inc. Methods of treating or preventing cachexia
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CA2565324A1 (en) 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
US7825138B2 (en) * 2004-06-29 2010-11-02 Helsinn Therapeutics (U.S.), Inc. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
HK1203394A1 (en) * 2012-05-25 2015-10-30 Raqualia Pharma Inc Ghrelin receptor agonists for the treatment of achlorhydria
MY187167A (en) 2014-09-04 2021-09-07 Helsinn Healthcare Sa Medical treatments based on anamorelin

Also Published As

Publication number Publication date
EP3188599A1 (en) 2017-07-12
JP7044918B2 (ja) 2022-03-30
US20210093627A1 (en) 2021-04-01
KR20170047372A (ko) 2017-05-04
KR101881264B1 (ko) 2018-07-23
HUE046894T2 (hu) 2020-04-28
MA40607B1 (fr) 2019-11-29
MD4710C1 (ro) 2021-04-30
CA2959158A1 (en) 2016-03-10
MD4710B1 (ro) 2020-09-30
US20170296526A1 (en) 2017-10-19
JP2021080281A (ja) 2021-05-27
KR20210035923A (ko) 2021-04-01
EP3590338A2 (en) 2020-01-08
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
NZ729673A (en) 2023-09-29
LT3188599T (lt) 2019-12-10
US11723902B2 (en) 2023-08-15
TW201613587A (en) 2016-04-16
SI3188599T1 (sl) 2020-02-28
AU2015312231A1 (en) 2017-03-23
UY36286A (es) 2016-02-29
US9675600B2 (en) 2017-06-13
TN2017000040A1 (en) 2018-07-04
US20240024303A1 (en) 2024-01-25
PL3188599T3 (pl) 2020-06-01
TWI639429B (zh) 2018-11-01
RS59751B1 (sr) 2020-02-28
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
JP2018154655A (ja) 2018-10-04
EP3590338A3 (en) 2020-03-18
UA120765C2 (uk) 2020-02-10
KR102234319B1 (ko) 2021-04-01
ES2761777T3 (es) 2020-05-21
DOP2017000055A (es) 2017-08-15
CY1122746T1 (el) 2021-03-12
MY187167A (en) 2021-09-07
BR112017003552A2 (pt) 2017-12-05
CN113577074A (zh) 2021-11-02
CN113577073A (zh) 2021-11-02
PT3188599T (pt) 2020-01-15
CN107375285A (zh) 2017-11-24
GEAP201814459A (en) 2018-09-10
JO3541B1 (ar) 2020-07-05
PH12017500392B1 (en) 2018-08-31
AP2017009772A0 (en) 2017-02-28
US10278964B2 (en) 2019-05-07
AU2015312231B2 (en) 2017-10-19
US20190175574A1 (en) 2019-06-13
ECSP17019893A (es) 2017-05-31
PH12017500392A1 (en) 2017-07-17
SG11201701567UA (en) 2017-03-30
ME03597B (me) 2020-07-20
IL250692B (en) 2019-05-30
US10894041B2 (en) 2021-01-19
CN109172575A (zh) 2019-01-11
CL2017000494A1 (es) 2017-09-15
KR102307275B1 (ko) 2021-09-30
JP6356907B2 (ja) 2018-07-11
EP3188599B1 (en) 2019-10-02
NI201700024A (es) 2017-07-18
CO2017003263A2 (es) 2017-07-28
SV2017005400A (es) 2017-04-20
MX2017002825A (es) 2017-09-28
HRP20192345T1 (hr) 2020-03-20
JP6923486B2 (ja) 2021-08-18
IL250692A0 (en) 2017-04-30
WO2016036598A1 (en) 2016-03-10
EP3188599A4 (en) 2017-10-11
JP2017526695A (ja) 2017-09-14
KR20180085047A (ko) 2018-07-25
PE20171109A1 (es) 2017-08-07
MX361741B (es) 2018-12-14
CN107205389A (zh) 2017-09-26
AR103118A1 (es) 2017-04-19
CR20170121A (es) 2017-07-17
US20160067236A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
MD20170025A2 (ro) Tratamente terapeutice pe bază de anamorelin
MX2021006768A (es) Metodos para tratar enfermedades oculares.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112017024212A2 (pt) sequências de uricases melhoradas e métodos de tratamento
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
EA201691567A1 (ru) Способы лечения легких травм головного мозга
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
AR102494A1 (es) Métodos para tratar enfermedades oculares
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
EA201991866A1 (ru) Комбинированная терапия
RU2014119669A (ru) Способ блокады подлопаточной мышцы
EA201492019A1 (ru) Способы лечения рака с помощью липопептидов
RU2014116784A (ru) Способ лечения заболеваний пародонта

Legal Events

Date Code Title Description
FG4A Patent for invention issued